Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.48 |
| ▸ | PIM1 | P11309 | 7/20 | 0.41 |
| ▸ | PIM3 | Q86V86 | 4/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.41 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.39 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.39 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | SMPD3 | Q9NY59 | 4/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28232709 | 0.79 | MAPT (0.42) | ROCK2ROCK1CDC42BPBPIM1PIM3 | |
| SCHEMBL6526399 | 0.79 | ROCK2 (0.51) | ROCK2ROCK1CDC42BPBPIM1PIM3 | |
| SCHEMBL6526402 | 0.79 | ROCK2 (0.51) | ROCK2ROCK1CDC42BPBPIM1PIM3 | |
| SCHEMBL4436851 | 0.76 | LMNA (0.59) | ROCK2ROCK1CDC42BPBPIM1PIM3 | |
| SCHEMBL4435478 | 0.76 | LMNA (0.59) | ROCK2ROCK1CDC42BPBPIM1PIM3 | |
| SCHEMBL4435482 | 0.76 | LMNA (0.59) | ROCK2ROCK1CDC42BPBPIM1PIM3 | |
| SCHEMBL30668708 | 0.71 | CHKA (0.57) | ROCK2ROCK1CDC42BPBSMARCA2SMARCA4 | |
| SCHEMBL24746251 | 0.71 | CHRNB2 (0.55) | — | |
| SCHEMBL5408335 | 0.71 | CHRNB2 (0.55) | — | |
| SCHEMBL29505484 | 0.71 | CHRNB2 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | ROCK2 519/4885ROCK1 453/4885CDC42BPB 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.